BeyondSpring (BYSI) Stock Price, News & Analysis

Company Overview

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Key Stats

• Today's Range: $1.71 to $1.79
• 50-Day Range: $1.53 to $1.79
• 52-Week Range: $1.05 to $4.00
• Volume: 3,186 shs
• Average Volume: 10,641 shs
• Market Capitalization: $69.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BYSI Stock Analysis - Frequently Asked Questions

How have BYSI shares performed this year?

BeyondSpring's stock was trading at $1.63 at the beginning of the year. Since then, BYSI stock has increased by 8.6% and is now trading at $1.77.
View the best growth stocks for 2025 here.

How were BeyondSpring's earnings last quarter?

BeyondSpring Inc. (NASDAQ:BYSI) released its quarterly earnings results on Wednesday, December, 29th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.11. The company earned $0.34 million during the quarter, compared to analyst estimates of $0.34 million.

When did BeyondSpring IPO?

BeyondSpring (BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.

Who are BeyondSpring's major shareholders?

Top institutional investors of BeyondSpring include Decheng Capital LLC (12.51%), Citadel Advisors LLC and Concourse Financial Group Securities Inc..

How do I buy shares of BeyondSpring?

Shares of BYSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of BeyondSpring own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BeyondSpring investors own include Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Alibaba Group (BABA), NIO (NIO), Bristol-Myers Squibb (BMY) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 12/29/2021
• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BYSI
• CUSIP: N/A
• CIK: 1677940
• Web: www.beyondspringpharma.com
• Phone: (646) 305-6387
• Fax: 1-646-882-4228
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.82
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.75 million
• Price / Sales: 39.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.91) per share
• Price / Book: -1.95

Miscellaneous

• Outstanding Shares: 39,030,000
• Free Float: 27,590,000
• Market Cap: $69.08 million
• Optionable: Optionable
• Beta: 0.27